PureTech Health (PRTC) Stock Price, News & Analysis

Company Overview

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies. Leading programs include LYT-100 (deupirfenidone), an anti-inflammatory/fibrotic agent in Phase 2 development for pulmonary and systemic indications; LYT-200, a novel antibody targeting tumor-associated antigens in colorectal cancer; and LYT-300, an enzyme-based therapy for primary hyperoxaluria. The company also maintains earlier-stage projects aimed at neurological conditions and immune-modulation.

Founded in 2005 by entrepreneur Daphne Zohar, PureTech Health is headquartered in Cambridge, Massachusetts, with additional operations in London. The company completed its initial public offering on the Nasdaq in 2020, building on a track record of strategic licensing and collaboration agreements with leading pharmaceutical partners. Its approach has generated several spin-out companies, enhancing shareholder value through focused clinical advancement and external partnerships.

Under the leadership of CEO and Founder Daphne Zohar, PureTech Health serves global markets through direct development and alliances. The organization emphasizes rigorous translational research, leveraging cross-disciplinary expertise to address high- unmet medical needs. By balancing in-house discovery with spin-out and partnership strategies, PureTech aims to deliver transformative therapies to patients worldwide.

Key Stats

• Today's Range: $16.90 to $17.54
• 50-Day Range: $14.73 to $18.29
• 52-Week Range: $14.50 to $19.92
• Volume: 20,995 shs
• Average Volume: 7,378 shs
• Market Capitalization: $420.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

PureTech Health Stock Analysis - MarketRank™

PureTech Health scored higher than 3% of companies evaluated by MarketBeat, and ranked 833rd out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

PureTech Health has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

PureTech Health has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

PureTech Health has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.11% of the float of PureTech Health has been sold short.

Short Interest Ratio / Days to Cover

PureTech Health has a short interest ratio ("days to cover") of 3.58, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PureTech Health has recently increased by 59.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PureTech Health does not currently pay a dividend.

Dividend Growth

PureTech Health does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for PureTech Health this week, compared to 1 article on an average week.

Search Interest

2 people have searched for PRTC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PureTech Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.30% of the stock of PureTech Health is held by insiders.

Percentage Held by Institutions

0.04% of the stock of PureTech Health is held by institutions.

Company Calendar

• Last Earnings: 4/10/2026
• Today: 5/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRTC
• CIK: 1782999
• Web: www.puretechhealth.com
• Phone: 617-482-2333
• Fax: 617-482-3337
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.59
• Quick Ratio: 6.59

Sales & Book Value

• Annual Sales: $4.66 million
• Price / Sales: 89.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.65 per share
• Price / Book: 1.36

Miscellaneous

• Outstanding Shares: 24,342,000
• Free Float: 23,052,000
• Market Cap: $418.93 million
• Optionable: Not Optionable
• Beta: 1.15